Observational study · people
Melanotan I: EPP quality-of-life score rose from 44% to 75%
Checked against the paper Observational studyPublished by PepVault
The takeaway
For people with EPP, this Dutch cohort links afamelanotide treatment to better disease-specific quality of life and social functioning, measured with patient questionnaires.
- Kind
- Observational study
- Studied in
- People
- Number studied
- 121
- Published
- 2023
- Journal
- J Dermatol
What they tested
The team wanted to learn how erythropoietic protoporphyria (EPP), a condition where light exposure brings on severe burning pain, affects daily and social life, and how that changed during afamelanotide treatment.
How the study was done
A single-center, prospective observational study that followed 121 adults with EPP at Erasmus MC Rotterdam in the Netherlands over time. Patients filled in questionnaires on their background, health and social life, including two general quality-of-life surveys (DS-14 and SF-36) and one made for EPP (EPP-QoL), before and during afamelanotide treatment.

What they found
Scores on EPP-QoL, the EPP-specific quality-of-life survey, went from 44% before treatment to 75% during afamelanotide treatment (p < 0.001). On the SF-36 social functioning scale, patients started below the Dutch population (74.4 ± 27.3 vs. 84.0 ± 22.4) and reached 84.3 ± 20.9 during treatment (p = 0.001). Among the 27.4% of patients with a Type-D personality, social inhibition scores improved during treatment (p = 0.019). Full- and part-time work went from 59.5% to 69.9%, but this change was not statistically significant (p > 0.05).
What it doesn’t show
This was a before-and-during comparison at one hospital with no control group and no placebo, so other factors could explain part of the change. The rise in employment did not reach statistical significance.
The paper
Wensink et al. Erythropoietic protoporphyria in the Netherlands: Clinical features, psychosocial impact and the effect of afamelanotide. J Dermatol. 2023.
The compound
More studies on Melanotan I
- Melanotan I: more pain-free sun time in protoporphyria trialsRandomized trial · people · 2015
- Melanotan I plus UV-B: 48.64% vitiligo repigmentation at day 168Randomized trial · people · 2015
- Melanotan I: full uptake under the skin, tanning in 3 menRandomized trial · people · 1997
- Melanotan I: well tolerated in 6 acute stroke patientsClinical trial · people · 2023
- Melanotan II: erections in 17 of 20 men with erectile dysfunctionClinical trial · people · 2000
- Melanotan II: darker skin in 2 of 3 men in a small phase I trialClinical trial · people · 1996
- Every study on Melanotan I
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.